LTRN

Lantern Pharma (LTRN)

Lantern Pharma Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:LTRN

1 2 3 4 5 6 7 8 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/09/23	21:00	Business Wire	Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers	NASDAQ:LTRN	Lantern Pharma Inc
2024/08/09	05:07	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:LTRN	Lantern Pharma Inc
2024/08/09	05:01	Business Wire	Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates	NASDAQ:LTRN	Lantern Pharma Inc
2024/08/07	22:31	Business Wire	Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024	NASDAQ:LTRN	Lantern Pharma Inc
2024/08/05	21:00	Business Wire	Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort	NASDAQ:LTRN	Lantern Pharma Inc
2024/08/01	21:00	Business Wire	Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET	NASDAQ:LTRN	Lantern Pharma Inc
2024/07/18	05:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LTRN	Lantern Pharma Inc
2024/07/18	05:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LTRN	Lantern Pharma Inc
2024/07/18	05:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LTRN	Lantern Pharma Inc
2024/07/18	05:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LTRN	Lantern Pharma Inc
2024/07/10	21:30	Business Wire	Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184	NASDAQ:LTRN	Lantern Pharma Inc
2024/06/18	05:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LTRN	Lantern Pharma Inc
2024/06/12	20:30	Business Wire	Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284	NASDAQ:LTRN	Lantern Pharma Inc
2024/06/11	13:16	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:LTRN	Lantern Pharma Inc
2024/05/25	05:09	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LTRN	Lantern Pharma Inc
2024/05/25	05:08	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:LTRN	Lantern Pharma Inc
2024/05/25	05:06	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:LTRN	Lantern Pharma Inc
2024/05/13	14:30	Business Wire	Oregon Therapeutics et Lantern Pharma lancent une collaboration stratégique dans le domaine de l’intelligence artificielle pour optimiser le développement du XCE853, premier candidat médicament de sa catégorie, un puissant inhibiteur...	NASDAQ:LTRN	Lantern Pharma Inc
2024/05/10	05:05	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:LTRN	Lantern Pharma Inc
2024/05/10	05:02	Business Wire	Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights	NASDAQ:LTRN	Lantern Pharma Inc
2024/05/06	16:00	Business Wire	Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism	NASDAQ:LTRN	Lantern Pharma Inc
2024/05/02	20:30	Business Wire	Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET	NASDAQ:LTRN	Lantern Pharma Inc
2024/04/24	21:00	Business Wire	Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development	NASDAQ:LTRN	Lantern Pharma Inc
2024/04/22	21:12	Business Wire	Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan	NASDAQ:LTRN	Lantern Pharma Inc
2024/03/19	05:02	Business Wire	Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights	NASDAQ:LTRN	Lantern Pharma Inc
2024/03/18	20:12	IH Market News	Anticipation Builds on Wall Street for Federal Reserve’s Upcoming Policy Moves; WTI and Brent See Upticks	NASDAQ:LTRN	Lantern Pharma Inc
2024/03/15	21:00	Business Wire	Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284	NASDAQ:LTRN	Lantern Pharma Inc
2024/03/11	20:30	Business Wire	Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET	NASDAQ:LTRN	Lantern Pharma Inc
2024/03/05	22:01	Business Wire	Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference	NASDAQ:LTRN	Lantern Pharma Inc
2024/03/04	22:01	Business Wire	Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines	NASDAQ:LTRN	Lantern Pharma Inc